KR20230171941A - 급성 폐손상 및 폐섬유증의 급성 악화를 개선하기 위한 의약 조성물 - Google Patents
급성 폐손상 및 폐섬유증의 급성 악화를 개선하기 위한 의약 조성물 Download PDFInfo
- Publication number
- KR20230171941A KR20230171941A KR1020237035872A KR20237035872A KR20230171941A KR 20230171941 A KR20230171941 A KR 20230171941A KR 1020237035872 A KR1020237035872 A KR 1020237035872A KR 20237035872 A KR20237035872 A KR 20237035872A KR 20230171941 A KR20230171941 A KR 20230171941A
- Authority
- KR
- South Korea
- Prior art keywords
- chain variable
- variable region
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
- G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021046301 | 2021-03-19 | ||
| JPJP-P-2021-046301 | 2021-03-19 | ||
| JP2021173381 | 2021-10-22 | ||
| JPJP-P-2021-173381 | 2021-10-22 | ||
| PCT/JP2022/012823 WO2022196816A1 (ja) | 2021-03-19 | 2022-03-18 | 急性肺障害および肺線維症の急性増悪を改善するための医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230171941A true KR20230171941A (ko) | 2023-12-21 |
Family
ID=83320552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237035872A Pending KR20230171941A (ko) | 2021-03-19 | 2022-03-18 | 급성 폐손상 및 폐섬유증의 급성 악화를 개선하기 위한 의약 조성물 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20260116957A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4310099A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2022196816A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230171941A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022239051A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3214262A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023010992A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022196816A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116570716B (zh) * | 2023-04-28 | 2025-05-16 | 水木星辰生物制药(深圳)有限公司 | lncRNA LOC646762表达的抑制剂的应用和药物 |
| CN117327147B (zh) * | 2023-09-26 | 2024-05-10 | 广东海洋大学 | 一种抗急性肺损伤多肽及其应用 |
| WO2026134246A1 (ja) * | 2024-12-18 | 2026-06-25 | 国立大学法人三重大学 | Corisin発現非ヒト動物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021126957A1 (en) | 2019-12-17 | 2021-06-24 | Mie University | Methods and compositions for evaluating and treating fibrosis |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9622660D0 (en) * | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
| WO2014089209A2 (en) * | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| LT3071597T (lt) * | 2013-11-21 | 2020-10-12 | F. Hoffmann-La Roche Ag | Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai |
| JP6394441B2 (ja) * | 2014-04-07 | 2018-09-26 | 株式会社デンソー | 内燃機関の冷却装置 |
| US10280223B2 (en) * | 2014-07-09 | 2019-05-07 | Nippon Zenyaku Kogyo Co., Ltd. | Anti-canine PD-1 antibody or anti-canine PD-L1 antibody |
| EP3380521A1 (en) * | 2015-11-24 | 2018-10-03 | Eli Lilly and Company | Combination therapy for cancer |
| WO2017214456A1 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| EP3678717B1 (en) * | 2017-09-04 | 2026-07-08 | Wockhardt Limited | Autoinjector with a needle cover |
| EP3629024A1 (en) * | 2018-09-26 | 2020-04-01 | Assistance Publique - Hôpitaux de Marseille | Cd146 and uses thereof as a biomarker and as a therapeutic target in the diagnosis and treatment of fibrosis |
| EP3689373A1 (en) * | 2019-01-30 | 2020-08-05 | IDT Biologika GmbH | Inactivated apxia, apxiia and apxiiia toxins |
| JP2021046301A (ja) | 2019-09-19 | 2021-03-25 | 株式会社Screenホールディングス | フィルムの剥離装置及び、フィルムの剥離方法 |
| US11723926B2 (en) * | 2019-09-27 | 2023-08-15 | Starkage Therapeutics | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
| JP2021173381A (ja) | 2020-04-28 | 2021-11-01 | トヨタ自動車株式会社 | ファンカップリング装置の制御装置 |
-
2022
- 2022-03-18 JP JP2023507207A patent/JPWO2022196816A1/ja active Pending
- 2022-03-18 KR KR1020237035872A patent/KR20230171941A/ko active Pending
- 2022-03-18 WO PCT/JP2022/012823 patent/WO2022196816A1/ja not_active Ceased
- 2022-03-18 CA CA3214262A patent/CA3214262A1/en active Pending
- 2022-03-18 US US18/282,975 patent/US20260116957A1/en active Pending
- 2022-03-18 AU AU2022239051A patent/AU2022239051A1/en active Pending
- 2022-03-18 MX MX2023010992A patent/MX2023010992A/es unknown
- 2022-03-18 EP EP22771559.6A patent/EP4310099A4/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021126957A1 (en) | 2019-12-17 | 2021-06-24 | Mie University | Methods and compositions for evaluating and treating fibrosis |
Non-Patent Citations (19)
| Title |
|---|
| [비특허문헌 1] 1 King, T. E., Jr., Pardo, A. & Selman, M. Idiopathic pulmonary fibrosis. Lancet 378, 1949-1961, doi: 10.1016/S0140-6736 (11)60052-4 (2011). |
| [비특허문헌 10] Ley, B., Collard, H. R. & King, T. E., Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183, 431-440, doi: 10.1164/rccm.201006-0894CI (2011). |
| [비특허문헌 11] Dickson, R. P. et al. Radiographic Honeycombing and Altered Lung Microbiota in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med200, 1544-1547, doi: 10.1164/rccm.201903-0680LE (2019). |
| [비특허문헌 12] Han, M. K. et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2, 548-556, doi: 10.1016/S2213-2600(14)70069-4 (2014). |
| [비특허문헌 13] Huang, Y. et al. Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 196, 208-219, doi: 10.1164/rccm.201607-15250C (2017). |
| [비특허문헌 14] Molyneaux, P. L. et al. Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 195, 1640-1650, doi:10.1164/rccm.201607-14080C (2017). |
| [비특허문헌 15] Takahashi, Y. et al. Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis. Respir Resl9, 34, doi:10.1186/sl2931-018-0736-9 (2018). |
| [비특허문헌 16] Wang, J. et al. Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-gamma. ERJ Open Res 3, doi: 10.1183/23120541.00008-2017 (2017). |
| [비특허문헌 17] Molyneaux, P. L. et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res 18, 29, doi: 10.1186/sl2931-017-0511-3 (2017). |
| [비특허문헌 18] Weng, D. et al. The Role of Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Mediators Inflamm 2019, 5160694, doi: 10.1155/2019/5160694 (2019). |
| [비특허문헌 19] D'Alessandro-Gabazza, C. N. et al. A Staphylococcus pro-apoptotic peptide induces acute exacerbation of pulmonary fibrosis. Nat Commun 11, 1539, doi: 10.1038/s41467-020-15344-3 (2020). |
| [비특허문헌 2] 2 Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med370, 2071-2082, doi: 10.1056/NEJMoal402584 (2014). |
| [비특허문헌 3] King, T. E., Jr., Noble, P. W. & Bradford, W. Z. Treatments for idiopathic pulmonary fibrosis. N Engl J Med 371, 783-784, doi: 10.1056/NEJMcl407776 (2014). |
| [비특허문헌 4] King, T. E., Jr. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370, 2083-2092, doi: 10.1056/NEJMoal402582 (2014). |
| [비특허문헌 5] 5 Lederer, D. J. & Martinez, F. J. Idiopathic Pulmonary Fibrosis. N Engl J Med 378, 1811-1823, doi: 10.1056/NEJMral705751 (2018). |
| [비특허문헌 6] 6 Sgalla, G., Biffi, A. & Richeldi, L. Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history. Respirology 21, 427-437, doi: 10.1111/resp.l2683 (2016). |
| [비특허문헌 7] Kreuter, M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. Eur Respir J 55, doi: 10.1183/13993003.01760-2019(2020). |
| [비특허문헌 8] Collard, H. R. et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 194, 265-275, doi: 10.1164/rccm.201604-0801CI (2016). |
| [비특허문헌 9] Natsuizaka, M. et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 190, 773-779, doi: 10.1164/rccm.201403-05660C (2014). |
Also Published As
| Publication number | Publication date |
|---|---|
| US20260116957A1 (en) | 2026-04-30 |
| EP4310099A1 (en) | 2024-01-24 |
| JPWO2022196816A1 (cg-RX-API-DMAC7.html) | 2022-09-22 |
| AU2022239051A9 (en) | 2023-10-26 |
| MX2023010992A (es) | 2023-11-14 |
| AU2022239051A1 (en) | 2023-10-12 |
| WO2022196816A1 (ja) | 2022-09-22 |
| CA3214262A1 (en) | 2022-09-22 |
| EP4310099A4 (en) | 2025-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2580240T3 (en) | S100A4 ANTIBODIES AND THERAPEUTIC APPLICATIONS THEREOF | |
| US20260116957A1 (en) | Pharmaceutical composition for ameliorating acute lung injury and acute worsening of pulmonary fibrosis | |
| AU2016353552B2 (en) | N-terminal epitopes in Amyloid beta and conformationally-selective antibodies thereto | |
| CN115066435A (zh) | 针对lilrb2的单域抗体 | |
| EP4213801A1 (en) | Antigen-binding molecules that bind to porphyromonas gingivalis | |
| EP2248826B1 (en) | Antibody directed against pcrv | |
| EP3374382A1 (en) | Epitopes in amyloid beta and conformationally-selective antibodies thereto | |
| WO2023079442A2 (en) | Antigen-binding molecules that bind to porphyromonas gingivalis | |
| KR20080113239A (ko) | 녹농균의 외막 단백질 pa0427 | |
| US11485776B2 (en) | Antibodies against infectious diseases | |
| US10975131B2 (en) | Factor H-Fc immunotheraphy | |
| US9868784B2 (en) | Antibodies against the S100P protein for the treatment and diagnosis of cancer | |
| JPWO2009142086A1 (ja) | マイコプラズマ感染症用ワクチン組成物 | |
| CN117425672A (zh) | 用于改善急性肺损伤和肺纤维化急性加重的药物组合物 | |
| US20230357373A1 (en) | Methods and compositions for evaluating and treating fibrosis | |
| WO2023148894A1 (ja) | 歯の再生治療のためのusag-1を標的分子とした中和抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231019 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250318 Comment text: Request for Examination of Application |